BriaCell says DSMB backs continued Phase 3 Bria-IMT breast cancer trial with no new safety concerns

• Briacell received a sixth consecutive positive DSMB recommendation to continue its pivotal Phase 3 Bria-ABC trial in metastatic breast cancer.
• Results have not been presented; the update reflects an interim safety review rather than a readout of clinical efficacy.
• The DSMB identified no safety concerns to date, supporting continued enrollment without protocol changes.
• The study tests Bria-IMT with an immune checkpoint inhibitor under FDA Fast Track designation, a key de-risking signal for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605260730PRIMZONEFULLFEED9726120) on May 26, 2026, and is solely responsible for the information contained therein.